Jeff Pearson

@jeffpears0n

Senior Pharmacist in Infectious Diseases , proud alum

Boston, MA
Vrijeme pridruživanja: travanj 2009.

Tweetovi

Blokirali ste korisnika/cu @jeffpears0n

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @jeffpears0n

  1. 3. velj

    These types of culture results always send a chill down my spine...

    Poništi
  2. proslijedio/la je Tweet
    31. sij

    SAVE THE DATE! Thursday 2/13 from 8-9PM EST and will be teaming up for a pro-con debate on , we hope you will join us in this twitter debate! Which side are you on?🧐 🤓👾

    Prikaži ovu nit
    Poništi
  3. 28. sij

    What other notable allergy publications did I miss from 2019? I can’t catch them all, so let me know and I’ll be sure to give a shout-out! And don't miss the live webinar tonight at 5:30 EST! 8/8

    Prikaži ovu nit
    Poništi
  4. 28. sij

    And lastly, published an RPh-led allergy de-labelling service in Australia that showed this strategy to be safe and effective 7/8

    Prikaži ovu nit
    Poništi
  5. 28. sij

    And published findings from an RPh-led beta-lactam allergy interview that reduced fluoroquinolone prescribing 6/8

    Prikaži ovu nit
    Poništi
  6. 28. sij

    Even without skin testing, pharmacists can make a difference though! published a positive study focused on RPh-led de-labelling ward rounds 5/8

    Prikaži ovu nit
    Poništi
  7. 28. sij

    A prospective pilot also in showed the successful implementation of skin testing in a community hospital setting 4/8

    Prikaži ovu nit
    Poništi
  8. 28. sij

    This guide also had the most comprehensive review of pharmacy state regulations concerning skin testing to-date. At least 18 states allow RPhs to administer skin tests. If a future update to the table is made, Massachusetts is unfortunately not one of them (yet) 3/8

    Prikaži ovu nit
    Poništi
  9. 28. sij
    Prikaži ovu nit
    Poništi
  10. 28. sij

    PCN Allergies, day 7: I’ll end the week of links with a shout-out to all the awesome work done by pharmacists in this space this past year! See thread below for 5 RPh-led studies from 2019 & tune in tonight for the full presentation 1/8

    Prikaži ovu nit
    Poništi
  11. 28. sij

    Which goes hand-in-hand with this brief recent literature review in from September that proposes direct oral amoxicillin challenges in low-risk patients labelled with a

    Prikaži ovu nit
    Poništi
  12. 28. sij

    Also published this past year in in October, a meta-analysis of over 5000 patients with a reported showed that 94.4% of patients tolerated a systemic dose of a penicillin (either through graded challenge or test dose procedure)

    Prikaži ovu nit
    Poništi
  13. 28. sij

    PCN Allergies, day 6: skin testing for isn't necessary for most patients. This RCT from in June showed that direct oral amoxicillin challenges were safe and effective to rule out allergy in low-risk patients

    Prikaži ovu nit
    Poništi
  14. 26. sij

    This new skin test kit could provide a one-stop shop for skin testing. But until it is reviewed by the FDA, an oral amoxicilin challenge can be given to skin test-negative patients to improve the NPV of the assessment from ~95% to close to 100% 3/3

    Prikaži ovu nit
    Poništi
  15. 26. sij

    The only FDA-approved skin test reagent is Pre-Pen, which provides the major determinant penicilloyl polylysine. Minor determinants are used off-label, and IV amoxicillin isn't currently available in the US to administer as a skin test 2/3

    Prikaži ovu nit
    Poništi
  16. 26. sij

    PCN Allergies, day 5: The Penicillin Skin Test Kit, in addition to major and minor allergenic determinants, also contains an amoxicillin skin test. In this prospective study, it had a negative predictive value of 98% 1/3

    Prikaži ovu nit
    Poništi
  17. 25. sij

    PCN Allergies, day 4: A meta-analysis looked at cross-reactivity potential in patients. Cross-reactivity varied: 16.5% chance for cephalosporins with similar R1 side chains, 2.1% for cephs with different side chains, and 0.9% for carbapenems

    Poništi
  18. 24. sij
    Poništi
  19. 24. sij

    Also published was this prevalence study from the UK. With 2.3 million patients, they found a rate of 5.9%, which increased risk of antibiotic re-prescribing (RR 1.32), MRSA infection/colonization (RR 1.9), and mortality within a year (RR 1.08)

    Prikaži ovu nit
    Poništi
  20. 24. sij

    PCN Allergy Study, day 2: an enormous population-based data set was published by and . ~6 million PCN courses, only 25 cases of anaphylaxis (~1 in 240,000 exposures), which was only 0.067% of the new reports

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·